ALX 5407

Drug Profile

ALX 5407

Alternative Names: ALX5407

Latest Information Update: 22 Nov 2000

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NPS Pharmaceuticals
  • Class Antipsychotics
  • Mechanism of Action Glycine reuptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Schizophrenia

Most Recent Events

  • 22 Nov 2000 Discontinued-Preclinical for Schizophrenia in USA (Unknown route)
  • 10 Feb 2000 Allelix Biopharmaceuticals has merged with NPS Pharmaceuticals
  • 01 Jul 1998 Preclinical development for Schizophrenia in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top